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Carotid artery stenting is widely performed for extracranial
carotid artery stenosis. In-stent thrombosis is a rare but
potentially devastating complication. We present a case of
acute in-stent thrombosis immediately following stent insertion
and post-balloon dilatation in a 64-year-old male. Thrombosis
was successfully treated by intravenous tirofiban, a
glycoprotein IIb/IIIa receptor inhibitor.
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INTRODUCTION
Carotid artery stenting is increasingly performed
for moderate to severe extracranial carotid stenosis
and is reported to have similar stroke prevention
and risk compared to endarterectomy.1,2 Carotid
stent thrombosis is rare compared to coronary
artery stent thrombosis,3,4 however it can still
result in devastating complications.5 Although
glycoprotein IIb/IIIa receptor inhibitors (GPI)
have been effectively used in percutaneous
coronary intervention, with and without intra-
coronary stenting, adjunctive GPI use in carotid
stenting is unusual. There are several case reports
on abciximab, but none on tribofiban.6-8 We present
a case of acute in-stent thrombosis successfully
treated by intravenous tirofiban.
CASE REPORT
A 63-year-old male was admitted for management
of known carotid artery stenosis. Medical history
was significant for nasopharyngeal lymphoma
status post chemo and radiation therapy 14 years
ago, and two episodes of left middle cerebral
artery territory infarction, one and seven years
ago. Since the last event, he has been on anti-
platelet agents (aspirin 100 mg/d). Left common
carotid artery stenosis was diagnosed by MR
angiography two years ago. Other medications
include an oral hypoglycemic and anti-hyperten-
sive agent for diabetes mellitus and hypertension.
Neurologic examination showed no deficits.
Aspirin (100 mg/d) and clopidogrel (75 mg/d)
were administered for two weeks prior to the
procedure as usual preventive medication. A
digital subtraction angiography showed severe
(85%) long segmental stenosis of the left common
carotid and mild stenosis of the right vertebral
artery orifice (Fig. 1A). A 4,000 unit heparin bolus
was given pre-dilatation and 5000 units mixed to
1000 mL of normal saline was used for intra-pro-
cedure continuous infusion. After Savvy balloon
(4 × 40 mm, Cordis, Roden, Netherlands) pre-
dilatation of the stenotic left common carotid, a
SMART self-expandable carotid stent (7 × 80 mm,
Cordis, Miami, USA) was deployed. Due to resi-
dual stenosis, Savvy balloon (5 × 40 mm, Cordis,
Roden, Netherlands) post-dilatation was performed
for approximately 20 seconds. Immediately post-
dilatation, a small filling defect at the distal stent
aspect was noted (Fig. 1B). As the defect acutely
developed, we suspected acute platelet rich
thrombus. Parenteral antiplatelet agent, tirofiban,
was infused intravenously with 0.4 g/kg/minμ
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loading dose for 30 minutes, followed by 0.1 g/μ
kg/min continuous infusion. In-stent thrombus
was completely dissolved after 30 minutes of
infusion (Fig. 1C). There was no occlusion of the
distal intracranial vessels. He received continuous
infusion for the next 26 hours. Brain MRI after
tirofiban showed small asymptomatic acute infarc-
tion on the right occipital lobe in diffusion-weighted
images (Fig. 2). There were no hemorrhagic com-
plications. He was discharged without complica-
tion on the fourth post-procedure day.
DISCUSSION
Thrombosis can cause serious post-procedural
complications of stent occlusion or distal emboli-
zation, resulting in acute cerebral infarction. Acute
stent thrombosis rate is reported to be approxi-
mately 0.5%.3,9 In the CAVATAS (Carotid and
Vertebral Artery Transluminal Angioplasty Study)
trial, stroke occurred in 5% of patients im-
mediately or soon after balloon dilatation and
stenting. Although the incidence of stroke
attributable to acute stent thrombosis is unclear, a
substantial proportion is assumed to be a direct
result of stent thrombosis or an indirect result by
distal embolization.2 Several factors, including
mechanical plaque disruption, intimal injury, and
stent thrombogenicity predispose the patient to
thromboembolic events.10,11 Platelet adhesion,
activation, and aggregation play main roles in
mural thrombus formation. Considering the
mechanism of acute thrombosis, antiplatelet
agents may be the best candidates for rescue
treatment. GPIs prevent thrombus formation and
subsequent distal embolization by inhibiting the
final common pathway of platelet aggregation.
GPIs have the advantage of parenteral use, and
rapid and strong action compared to oral anti-
platelet agents. There are three GPIs (abciximab,
tirofiban, eptifibatide) available for clinical use;
significant differences exist in biological and
plasma half-life between abciximab and the small
molecule agents (tirofiban and eptifibatide). Various
trials of GPIs in percutaneous coronary inter-
Fig. 2. Brain diffusion-weighted MRI shows small high
signal lesions (arrow) in right occipital lobe.
Fig. 1. Digital subtraction cerebral angio-
graphy shows left common carotid artery
stenosis (A). Immediately after stent insertion
and balloon dilatation in-stent thrombus
(arrow) is seen (B). Thrombus disappears after
intravenous tirofiban infusion (C).
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vention showed favorable results. However,
several trials evaluating routine adjuvant GPI use
in carotid artery stent have demonstrated con-
flicting results. Kapadia et al. showed decreasing
procedural complications while other studies
showed increased hemorrhagic complications.10-13
Most clinical studies used abciximab, and little
data exists on tirofiban; abciximab was used alone
or combined with thrombolytics or mechanical
thrombectomy in acute stent thrombosis.6-8 Two
cases used doses (0.25 mg/kg intravenous bolus
and 0.125 g/kg/min for 12 hours intravenousμ
infusion) typically administered in coronary
artery disease and one case used a half dose (0.125
mg/kg) intra-arterially followed by a full dose 12
hour infusion. All cases reported patent ICA after
treatment. Tirofiban is a non-peptide tyrosin deri-
vative that mimics the RGD integrin recognition
sequence; it has a very short platelet-bound half-
life and relatively long plasma half-life. Therefore,
it has an advantage when rapid antiplatelet action
reversal is required, such as patients with a high
risk of hemorrhage or in combined use with
thrombolytics. When considering thrombolytics or
emergency surgical treatment in cases of GPI
failure, tirofiban may be more suitable than
abciximab. Furthermore, tirofiban is reported to
produce a dose-dependent dethrombotic effect on
stent thrombosis and inhibit acute de novo
thrombosis under high-shear flow conditions.14
Surgical management is another possible option
for acute stent thrombosis. However, as acute
thrombosis is rare, it is difficult to accumulate
evidence for a preferred treatment strategy.
Setacci et al. reported positive results of embo-
lectomy, with or without stent removal, in cases
of acute stent thrombosis following stenting while
surgical treatment was commonly used in cases of
thrombosis after endarterctomy.9,15,16 We chose
medical management rather than surgery, because
the event occurred in the angiography suite
allowing immediate drug infusion. In this case,
surgical intervention would have resulted in
substantial delay and increased time for ischemia.
Furthermore, we had the experience of GPI
success in acute thrombosis.17
This case demonstrates that intravenous tirofi-
ban can successfully resolve acute in-stent
thrombosis during carotid stent insertion. Until
the benefit of routine GPI adjuvant use is proven
by a large randomized clinical trial, GPIs should
not be recommended for routine use. However,
for intra-procedure thrombus, it can be an effec-
tive rescue treatment.6,17
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